1. Home
  2. SIG vs ERAS Comparison

SIG vs ERAS Comparison

Compare SIG & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Signet Jewelers Limited

SIG

Signet Jewelers Limited

HOLD

Current Price

$86.74

Market Cap

3.4B

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$15.17

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIG
ERAS
Founded
1950
2018
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
4.0B
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
SIG
ERAS
Price
$86.74
$15.17
Analyst Decision
Buy
Strong Buy
Analyst Count
7
12
Target Price
$111.14
$14.25
AVG Volume (30 Days)
933.1K
5.4M
Earning Date
06-02-2026
05-08-2026
Dividend Yield
1.65%
N/A
EPS Growth
974.07
36.23
EPS
0.78
N/A
Revenue
$6,247,100,000.00
N/A
Revenue This Year
$1.39
N/A
Revenue Next Year
$1.71
N/A
P/E Ratio
$107.23
N/A
Revenue Growth
N/A
N/A
52 Week Low
$71.62
$1.24
52 Week High
$110.20
$24.28

Technical Indicators

Market Signals
Indicator
SIG
ERAS
Relative Strength Index (RSI) 51.63 61.26
Support Level $81.23 $14.00
Resistance Level $95.59 $16.14
Average True Range (ATR) 4.01 1.00
MACD -0.28 0.19
Stochastic Oscillator 36.32 83.67

Price Performance

Historical Comparison
SIG
ERAS

About SIG Signet Jewelers Limited

Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding, and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Outlet. Geographically, it operates in the USA, Canada, the UK, and Ireland, with the maximum revenue from the USA.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: